ASP2215 – Sponsored by Astellas Pharama Global DevelopmentActive Study | Duration: ?? weeks
The Virginia Cancer Center, one of the leading cancer facilities on the East Coast, is collaborating with RGW on a study assessing the safety of the drug ASP2215.
The objective is to evaluate its safety and tolerability, including the maximum tolerated dose of ASP2215 in subjects with relapsed or treatment-refractory acute myeloid leukemia (AML). It will also determine the pharmacokinetic (PK) parameters of the drug.
This study is being conducted at our Fairfax, Va. office.